Abstract
Monoclonal and polyclonal antibody preparations have been used for induction therapy after organ transplantation. Apart from serious adverse effects directly associated with their administration, for example the cytokine release syndrome, the resulting profound and aspecific immunosuppression leads to increased incidences of infections and, in the long term, of malignancies. To avoid the drawbacks of this aselective immunosuppression, monoclonal antibodies (mAbs) against specific T cell activation determinants have been developed. In view of the pivotal role of interleukin-2 in the activation cascade of antigen-stimulated lymphocytes, mAbs directed against the interleukin-2 receptor (IL-2R) are believed to have a strong inhibitory effect only on activated T cells.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
